Selumetinib available in Australia
Over the weekend Selumetinib was added to the Australian Register of Therapeutic Goods (ARTG) under the Black Triangle scheme. This means Selumetinib can now be offered in Australia on compassionate grounds. We reached out to the AstraZeneca Australia team who were able to advise that requests for access by a treating clinician under compassionate grounds will continue to be reviewed on a case-by-case basis by the global team. AstraZeneca are now working toward having the medication listed on the PBS.
Selumetinib was approved by the FDA in the US in 2020 and has shown remarkable results. The US National Cancer Institute’s Pediatric Oncology Branch, has been able to show that the drug shrank neurofibromas in 70% of patients. For many children in the trial, treatment with selumetinib also had clinical benefit, improving their pain, function, and quality of life.
We have included a helpful article that was published last year that explains more.
